The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum

Pancreas

Volumn 39, Issue 6, 2010, Pages 753-766

  Boudreaux, J Philip ^a   Klimstra, David S ^b   Hassan, Manal M ^c   Woltering, Eugene A ^a   Jensen, Robert T ^d   Goldsmith, Stanley J ^e   Nutting, Charles ^f   Bushnell, David L ^g   Caplin, Martyn E ^h   Yao, James C ^c  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e Department of Obstetrics Gynecology   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^h ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

appendix; cecum; ileum; jejunum; neuroendocrine tumors

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ALPHA INTERFERON; ANGIOPEPTIN; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CHROMOGRANIN; CORTICOSTEROID; DOPAMINE; DOXORUBICIN; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; KI 67 ANTIGEN; KREON; LONG ACTING DRUG; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE; OCTREOTIDE; PANCRELIPASE; PHENYLEPHRINE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN; SORAFINIB; STREPTOZOCIN; SUNITINIB; SYNAPTOPHYSIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASOPRESSIN;

ANEMIA; ANOREXIA; ANTIBODY LABELING; APPENDIX; BOLUS INJECTION; BONE MARROW TOXICITY; BRADYCARDIA; BRONCHOSPASM; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOID SYNDROME; CARDIOVASCULAR DISEASE; CECUM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG INFUSION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FLUSHING; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; ILEUM; IMAGING SYSTEM; IMMUNOCYTOCHEMISTRY; INCIDENCE; JEJUNUM; LEUKOPENIA; LOADING DRUG DOSE; MALABSORPTION; MEDICAL SOCIETY; METASTASIS; MIDGUT; MOLECULAR GENETICS; NEUROENDOCRINE TUMOR; NICOTINIC ACID DEFICIENCY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELLAGRA; PERIOPERATIVE PERIOD; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; REVIEW; RISK FACTOR; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SURGICAL TECHNIQUE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR VOLUME; VASOMOTOR DISORDER; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; WHEEZING; WORLD HEALTH ORGANIZATION;

APPENDIX; CECUM; HUMANS; ILEUM; INTESTINAL NEOPLASMS; JEJUNUM; NEUROENDOCRINE TUMORS;

EID: 77955226386     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181ebb2a5     Document Type: Review

References (61)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after Bcarcinoid[: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063-3072.
2. Berg JW, Godwin JD 2nd. The epidemiologic pathology of carcinomas of the large bowel. J Surg Oncol. 1974;6:381-400.
3. Moertel CG, Sauer WG, Docherty MB, et al. Life history of the carcinoid tumor of the small intestine. Cancer. 1961;14:291-293.
4. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: SEER 17 Regs Nov 2006 sub (1973-2004) (ed released April 2006). Available at: www.seer.cancer.gov. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistic Branch; 2006.
5. Hassan MM, Phan A, Li D, et al. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev. 2008;17:959-965. (Pubitemid 351536429)
6. Hiripi E, Bermejo JL, Sundquist J, et al. Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol. 2009; 20:950-954.
7. Chen CC, Neugut AI, Rotterdam H. Risk factors for adenocarcinomas and malignant carcinoids of the small intestine: preliminary findings. Cancer Epidemiol Biomarkers Prev. 1994;3:205-207.
8. Chow WH, Linet MS, McLaughlin JK, et al. Risk factors for small intestine cancer. Cancer Causes Control. 1993;4:163-169.
9. Kaerlev L, Teglbjaerg PS, Sabroe S, et al. The importance of smoking and medical history for development of small bowel carcinoid tumor: a European population-based case-control study. Cancer Causes Control. 2002;13:27-34.
10. Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer. 2008;123:867-873. (Pubitemid 352032414)
11. Cross AJ, Leitzmann MF, Subar AF, et al. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res. 2008;68:9274-9279.
12. Schatzkin A, Park Y, Leitzmann MF, et al. Prospective study of dietary fiber, whole grain foods, and small intestinal cancer. Gastroenterology. 2008;135:1163-1167.
13. Tang LH, Shia J, Soslow RA, et al. Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol. 2008;32:1429-1443.
14. Guo Z, Li Q,Wilander E, et al. Clonality analysis of multifocal carcinoid tumours of the small intestine by X-chromosome inactivation analysis. J Pathol. 2000;190:76-79.
15. Choi IS, Estecio MR, Nagano Y, et al. Hypomethylation of LINE-1 and Alu in well-differentiated neuroendocrine tumors ( pancreatic endocrine tumors and carcinoid tumors). Mod Pathol. 2007;20:802-810.
16. Semelka RC, Custodio CM, Cem Balci N, et al. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging. 2000;11:141-148.
17. Pamuklar E, Semelka RC. MR imaging of the pancreas. Magn Reson Imaging Clin N Am. 2005;13:313-330.
18. Kelekis NL, Semelka RC. MRI of pancreatic tumors. Eur Radiol. 1997;7:875-886.
19. Dromain C, de Baere T, Baudin E, et al. MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. Am J Roentgenol. 2003;180:121-128.
20. Debray MP, Geoffroy O, Laissy JP, et al. Imaging appearances of metastases from neuroendocrine tumours of the pancreas. Br J Radiol. 2001;74:1065-1070.
21. Krenning EP, Kooij PPM, Bakker WH, et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. Ann N Y Acad Sci. 1994;733:496-506.
22. Balon HR, Goldsmith SJ, Siegel BA, et al. Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide. J Nucl Med. 2001;42:1134-1138.
23. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5- hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90:3392-3400.
24. Goebel SU, Serrano J, Yu F, et al. Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer. 1999;85:1470-1483. (Pubitemid 29152818)
25. Bernini GP, Moretti A, Ferdeghini M, et al. A new human chromogranin FA- immunoradiometric assay for the diagnosis of neuroendocrine tumours. Br J Cancer. 2001;84:636-642.
26. Nehar D, Lombard-Bohas C, Olivieri S, et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf ). 2004;60:644-652.
27. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86:858-865.
28. Tormey WP, FitzGerald RJ. The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid. Postgrad Med J. 1995;71:542-545.
29. Feldman J, Lee E. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr. 1985;42:639-643.
30. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934-959.
31. Oberg K, Astrup L, Eriksson B, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part IVgeneral overview. Acta Oncol. 2004;43:617-625. (Pubitemid 39563934)
32. Honig LJ, Weingarten G. A gastric carcinoid tumor with massive bleeding. Am J Gastroenterol. 1974;61:40-44.
33. Kinney MA, Warner ME, vanHeerden JA, et al. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection. Anesth Analg. 2000;91:1118-1123.
34. Parris WC, Oates JA, Kambam J, et al. Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome. Can J Anaesth. 1988;35:413-416.
35. Quinlivan JK, Roberts WA. Intraoperative octreotide for refractory carcinoid-induced bronchospasm. Anesth Analg. 1994;78:400-402.
36. Claure RE, Drover DD, Haddow GR, et al. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management. Can J Anaesth. 2000;47:334-337.
37. Orbach-Zinger S, Lombroso R, Eidelman LA. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide. Can J Anaesth. 2002;49:678-681.
38. Anthony LB, Stafford S, Cronin M, et al. Octreotide LAR doses used in clinical practice: results from an internet survey and a clinical practice. In: Gary A, ed. Annual Meeting of the American Society of Clinical Oncology. New Orleans, LA: American Society of Clinical Oncology; 2004:381.
39. Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600-606.
40. Biesma B, Willemse PH, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer. 1992;66:850-855.
41. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs. 1994;5:503-519.
42. Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol. 1992;3:35-41.
43. Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon- alpha in patients with metastatic carcinoid tumorsVan antiangiogenic effect? Anticancer Drugs. 1996;7:175-181.
44. Janson EM, Ahlstrom H, Andersson T, et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer. 1992;10:1647-1650.
45. Smith DB, Scarffe JH, Wagstaff J, et al. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep. 1987;71:1265-1266.
46. Doberauer C, Mengelkoch B, Kloke O, et al. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncol. 1991;30:603-605.
47. Creutzfeldt W, Bartsch HH, Jacubaschke U, et al. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol. 1991;30:529-535.
48. Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer. 1993;72:3099-3105.
49. Di Bartolomeo M, Bajetta E, Zilembo N, et al. Treatment of carcinoid syndrome with recombinant interferon alpha-2a [published correction appears in Acta Oncol 32:592;1993]. Acta Oncol. 1993; 32:235-238.
50. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12(suppl 2):S111-S114.
51. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:617-636.
52. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394-424.
53. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656-4663.
54. Schnirer II, Yao JC, Ajani JA. Carcinoid: a comprehensive review. Acta Oncol. 2003;42:672-692.
55. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26:4311-4318.
56. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26:1316-1323.
57. Maroun J, Kocha W, Kvols L, et al. Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group. Curr Oncol. 2006;13:67-76.
58. Vogl TJ, Naguib NN, Zangos S, et al. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. Eur J Radiol. 2009;72: 517-528.
59. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg. 2001;25:693-696.
60. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer. 2005;104:1590-1602.
61. Jones A, Alexander HR Jr. Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies. Surg Oncol Clin N Am. 2008;17:857-876, x.